← All trials
NCT05115942
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 20, 2021
- Primary completion
- Mar 30, 2024
- Completion date
- Jun 30, 2024
- First posted
- Nov 10, 2021
- Last posted
- Nov 10, 2021
- Enrollment
- 248
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- GNI GroupLead sponsor
- Jiao Tong UniversityOverall official - principal investigator
- Capital Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.